NCT01729754View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)

PHASE3CompletedINTERVENTIONAL

Enrollment

1,090

Participants

Timeline

Start Date

February 5, 2013

Primary Completion Date

September 28, 2015

Study Completion Date

October 26, 2021

Conditions

Plaque Psoriasis

Interventions

DRUG

Tildrakizumab 200 mg

Tildrakizumab 200 mg administered SC. Each pre-filled syringe (PFS) or autoinjector (AI) contains 1 mL of solution, tildrakizumab 100 mg/mL.

DRUG

Tildrakizumab 100 mg

Tildrakizumab 100 mg administered SC. Each PFS or AI contains 1 mL of solution, tildrakizumab 100 mg/mL.

DRUG

Tildrakizumab Placebo

Matching placebo to tildrakizumab administered SC

DRUG

Etanercept Placebo

Matching placebo to etanercept administered SC

DRUG

Etanercept 50 mg

Etanercept 50 mg administered SC

All Listed Sponsors

lead

Sun Pharmaceutical Industries Limited

INDUSTRY

NCT01729754 - A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011) | Biotech Hunter | Biotech Hunter